Status:

TERMINATED

Intermittent Negative Pressure; Impact on Peripheral Artery Disease and Intermittent Claudication

Lead Sponsor:

Otivio AS

Collaborating Sponsors:

mediq Innovation Experts GmbH

Hannover Medical School

Conditions:

Peripheral Vascular Disease

Intermittent Claudication

Eligibility:

All Genders

18+ years

Phase:

NA

Brief Summary

The objective is to ensure the pro-active collection of information on quality, safety and performance of FlowOx™ after it is placed on the market. The study will be carried out in a patient populatio...

Detailed Description

A multi-center, randomized, sham (placebo)-controlled, double-blind trial to assess the efficacy and safety of FlowOx. This is done by comparing the increase in pain free walking distance compared to ...

Eligibility Criteria

Inclusion

  • Male or female outpatients, age greater or equal 18 years
  • Stable evidence based pAVK therapy for at least 3 months
  • Ability to perform a treadmill test
  • Confirmation of clinical diagnosis of PAD as objective evidence of Fontaine stage IIb PAD i.e.:
  • Reduced ankle systolic blood pressure (ABI \<0.9) on target leg
  • Pain free walking distance \< 200 m in standardized walking test (initial claudication distance (ICD))
  • Completion of at least two treadmill tests within a time interval of greater or equal to 1 week prior to randomisation. Maximum change in claudication should not exceed a predefined threshold (\<25% for the absolute claudication distance (ACD)).
  • Intermittent claudication lasting for at least 3 months
  • Stable smoking habits for at least 3 months prior to inclusion
  • Signed Informed Consent

Exclusion

  • PAOD-patients with critical limb ischemia (CLI), equivalent to EMA's or Fontaine's PAOD-stages III and IV
  • Any kind of revascularization (endovascular, surgical) in the iliac or other leg arteries within 3 months prior to Visit 1
  • Patients with polyneuropathy
  • Other illnesses limiting exercise capacity (angina pectoris, heart failure, respiratory disease, orthopedic disease, neurological disorders)
  • Use of confounding medications within the last 4 weeks prior the Visit 1 e.g. vasoactive compounds like Cilostazol or Naftidrofuryl
  • Uncontrolled hypertension (\> 180/95 mmHg) or hypotension (supine \< 100 mmHg)
  • Severe anemia
  • Pregnancy or lactation period
  • Woman with childbearing potential without an effective contraceptive method (effective contraception method: hormonal contraceptive, hormonal vaginal devices or injections with prolonged release; an intrauterine device, or a barrier method of contraception such as condom or occlusive cap with spermicide (foam/gel/film/cream/suppository)
  • Planned surgical intervention requiring hospitalization during the clinical trial
  • Previous inclusion in the present clinical trial or parallel participation in other clinical trials (up to 8 weeks before Visit 1)
  • Incapability of understanding nature, meaning and consequences of the clinical trial
  • Patient unable to read and or write
  • Patients in custody by juridical or official order
  • Patients, who are members of the staff of the trial centre, staff of the sponsor or involved Clinical Research Organizations (CRO's), the investigator him-/herself or close relatives of the investigator
  • Patients unable to don or doff the FlowOx device (either themselves or with assistance from a helper).
  • Diagnosed acute deep vein thrombosis
  • Systemic infection
  • Alcohol disease or drug abuse
  • Malignant disease

Key Trial Info

Start Date :

August 19 2019

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

May 31 2020

Estimated Enrollment :

16 Patients enrolled

Trial Details

Trial ID

NCT04100681

Start Date

August 19 2019

End Date

May 31 2020

Last Update

August 25 2020

Active Locations (5)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 2 (5 locations)

1

Franziskus-Krankenhaus Berlin

Berlin, Germany, 10787

2

Evangelisches Krankenhaus Hubertus, Gefäßzentrums Berlin-Brandenburg

Berlin, Germany, 14129

3

Gemeinschaftspraxis

Ettlingen, Germany, 76275

4

Universitätsmedizin Göttingen Georg-August-Universität

Göttingen, Germany, 37075